Hoda Tawfik

Company: InflaRx N.V.

Job title: Immunoderm Program Director

Seminars:

Vilobelimab, a First-In-Class Anti-C5a Antibody for the Treatment of the Neutrophil Driven Skin Diseases Hidradenitis Suppurativa & Pyoderma Gangraenosum 2:50 pm

Revisiting the role of C5a in neutrophil driven skin diseases Connecting the dots – vilobelimab development for neutrophil driven skin diseases A view on endpoints for HS – whatmatters for patients?Read more

day: Day Two